-
1
-
-
0038151908
-
Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: Evidence for the existence of multiple pathways of tissue destruction and repair
-
van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun. 4:2003;187-196
-
(2003)
Genes Immun
, vol.4
, pp. 187-196
-
-
Vander Pouw Kraan, T.C.1
Van Gaalen, F.A.2
Huizinga, T.W.3
Pieterman, E.4
Breedveld, F.C.5
Verweij, C.L.6
-
2
-
-
0037451167
-
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
-
Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 97:2003;711-723
-
(2003)
J Exp Med
, vol.97
, pp. 711-723
-
-
Bennett, L.1
Palucka, A.K.2
Arce, E.3
-
3
-
-
2942548838
-
A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells
-
Olsen NJ, Sokka T, Seehorn CL, Kraft B, Moore J, Aune TM. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 63:2004;1387-1392
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1387-1392
-
-
Olsen, N.J.1
Sokka, T.2
Seehorn, C.L.3
Kraft, B.4
Moore, J.5
Aune, T.M.6
-
4
-
-
0035042925
-
What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?
-
March L, Lapsley H. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Best Pract Res Clin Rheumatol. 15:2001;171-185
-
(2001)
Best Pract Res Clin Rheumatol
, vol.15
, pp. 171-185
-
-
March, L.1
Lapsley, H.2
-
5
-
-
0033959698
-
Subspecialty referrals for pauciarticular juvenile rheumatoid arthritis
-
Cuesta I, Kerr KL, Jarvis JN. Subspecialty referrals for pauciarticular juvenile rheumatoid arthritis. Arch Pediatr Adolescent Med. 154:2000;122-125
-
(2000)
Arch Pediatr Adolescent Med
, vol.154
, pp. 122-125
-
-
Cuesta, I.1
Kerr, K.L.2
Jarvis, J.N.3
-
6
-
-
3242886819
-
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
-
Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 43:2004;906-914
-
(2004)
Rheumatology
, vol.43
, pp. 906-914
-
-
Nell, V.P.1
MacHold, K.P.2
Eberl, G.3
Stamm, T.A.4
Uffmann, M.5
Smolen, J.S.6
-
7
-
-
0037317182
-
An associative analysis of gene expression array data
-
Dozmorov I, Centola M. An associative analysis of gene expression array data. Bioinformatics. 19:2003;204-211
-
(2003)
Bioinformatics
, vol.19
, pp. 204-211
-
-
Dozmorov, I.1
Centola, M.2
-
8
-
-
85182493459
-
Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis
-
Jarvis JN, Dozmorov I, Jiang K, et al. Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 6:2004;R15-R32
-
(2004)
Arthritis Res Ther
, vol.6
-
-
Jarvis, J.N.1
Dozmorov, I.2
Jiang, K.3
-
9
-
-
2942625428
-
Clinical impact of gene expression profiling on oncology diagnosis, prognosis, and treatment
-
Kim AS. Clinical impact of gene expression profiling on oncology diagnosis, prognosis, and treatment. Combinatorial Chem High Throughput Screening. 7:2004;183-206
-
(2004)
Combinatorial Chem High Throughput Screening
, vol.7
, pp. 183-206
-
-
Kim, A.S.1
-
10
-
-
8444220472
-
Gene expression microarray technologies in the development of new therapeutic agents
-
Clarke PA, Poele RT, Workman P. Gene expression microarray technologies in the development of new therapeutic agents. Eur J Cancer. 40:2004;2560-2591
-
(2004)
Eur J Cancer
, vol.40
, pp. 2560-2591
-
-
Clarke, P.A.1
Poele, R.T.2
Workman, P.3
|